Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION

Autor:	Ehab Atallah, Jorge E. Cortes, Oumar Sy, Michael J. Mauro, Neil P. Shah, Mena Abaskharoun, Andreas Hochhaus, Giuseppe Saglio
Rok vydání:	2017
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Myeloid leukemia Imatinib Hematology Newly diagnosed medicine.disease Comorbidity Dasatinib Internal medicine Medicine In patient Chronic phase CML business medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 17:S312-S313
ISSN:	2152-2650
DOI:	10.1016/j.clml.2017.07.113
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::73189b169b1b4a1b36b4316358546782 https://doi.org/10.1016/j.clml.2017.07.113 Zobrazit plný text záznamu Full Text from ScienceDirect